New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

Legendary former Republic of Ireland star appears on RTE's The Late Late Show this evening as we celebrate the legends of ...

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

An obituary for a 77-year-old woman has caught the attention of social media, with one declaring, “Who is this icon?” ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...